CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Zanubrutinibdrug
Likely dose
Zanubrutinib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05068440
NCT05068440Phase 2Completed
CompareCT.gov

A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib in Patients With CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeiGene·interventional·Posted Oct 5, 2021·Updated Mar 25, 2026

In Brief

A Phase 2 clinical trial evaluating Zanubrutinib for Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma. Completed, enrolled 65 participants across 25 sites.

Detailed Summary

The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Participants received zanubrutinib as monotherapy, underwent regular disease assessments to evaluate treatment response, and were monitored for safety and side effects throughout the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 5, 2021
Enrollment StartAug 11, 2021
Primary CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.7 years ago

Interventions

Zanubrutinibdrug

Administered orally as capsules at a dose of 160 mg twice daily on a continuous dosing schedule.